Oncolytic Sendai virus for brain-tsupmeorcific immune-gene therapy

用于脑肿瘤免疫基因治疗的溶瘤仙台病毒

• 批准号: 22591606
• 负责人: IWADATE Yasuo
• 金额: $ 2.83万
• 依托单位: Chiba University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2010
• 资助国家: 日本
• 起止时间: 2010 至 2012
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-22591606/
• 关键词: 脳腫瘍学; ウイルス療法; 腫瘍特異的免疫; インターフェロン; 遺伝子組み換え; グリオーマ; 腫瘍免疫; センダイウイルス; Flt3-L; 遺伝子組換え

Glioblastoma (GM) is highly invasive due to the expression of proteases including urokinase-type plasminogen activator (uPA). A new recombinant Sendai virus (rSeV) showing uPA-specific cell-to-cell fusion activity [rSeV/dMFct14 (uPA2)] was shown to be effective for GM treatment, especially with the interferon-β (IFN-β) gene integration. There were marked infiltration of CD8 T cell, CD4 T cell, and CD11b+ cells in the brain tumor tissues. Flt3-L was also highly positive in the tumor tissues treated with rSeV/dMFct14 (uPA2)/ IFNβ, which was considered to be the molecular background of the prominent immunogeneicity. There were no adverse events observed in the long-survived rats. Therefore, these results suggest that rSeV/dMFct14 (uPA2)/ IFNβ may have a significant potential to improve the survival of GM patients in a clinical setting.

胶质母细胞瘤（GM）由于蛋白酶（包括尿激酶型纤溶酶原激活物（uPA））的表达而具有高度侵袭性。一种新的重组仙台病毒（rSeV）显示uPA特异性细胞间融合活性[rSeV/dMFct 14（uPA 2）]，被证明是有效的GM治疗，特别是与干扰素-β（IFN-β）基因整合。脑肿瘤组织中CD 8 T细胞、CD 4 T细胞和CD 11b+细胞浸润明显。Flt 3-L在rSeV/dMFct 14（uPA 2）/ IFNβ处理的肿瘤组织中也呈高度阳性，这被认为是其显著免疫原性的分子背景。在长期存活的大鼠中未观察到不良事件。因此，这些结果表明，rSeV/dMFct 14（uPA 2）/ IFNβ可能具有在临床环境中改善GM患者存活的显著潜力。

项目成果

Anaplastic oligodendroglial tumors harboring 1p/19q deletion can be successfully treated without radiotherapy.

含有 1p/19q 缺失的间变性少突胶质细胞瘤无需放疗即可成功治疗。

• 发表时间: 2011
• 期刊: Anticancer research
• 影响因子: 2
• 作者: Y. Iwadate;T. Matsutani;Natsuki Shinozaki;N. Saeki
• 通讯作者: N. Saeki

シグナル伝達系タンパク抗体アレイによる膠芽腫の新規予後因子

使用信号转导系统蛋白抗体阵列研究胶质母细胞瘤的新预后因素

• 发表时间: 2012
• 作者: 岩立康男;篠崎夏樹;池上史郎;松谷智郎;佐伯直勝
• 通讯作者: 佐伯直勝

大量MTX療法単独による中枢神経系原発悪性リンパ腫の初期治療

单独使用大剂量 MTX 治疗原发性中枢神经系统恶性淋巴瘤的初始治疗

• 发表时间: 2012
• 期刊: 癌と化学療法
• 作者: 5.Matsutani T;Hiwasa T;Takiguchi M;Oide T;Kunimatsu M;Saeki N;Iwadate Y;Sugawara T;岩立康男
• 通讯作者: 岩立康男

Experience With Carbon Ion Radiotherapy for WHO Grade 2 Diffuse Astrocytomas

• DOI: 10.1016/j.ijrobp.2011.06.1952
• 发表时间: 2012-05-01
• 期刊: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
• 影响因子: 7
• 作者: Hasegawa, Azusa;Mizoe, Jun-Etsu;Takakura, Kintomo
• 通讯作者: Takakura, Kintomo

Urokinase-targeted fusion by oncolytic Sendai virus eradiacates orthotopic glioblastomas by pronounced synergy with interferon-βgene

溶瘤仙台病毒的尿激酶靶向融合通过与干扰素-β基因的显着协同作用根除原位胶质母细胞瘤

• 发表时间: 2010
• 期刊: Mol Ther 18
• 作者: Hasegawa Y;Iwadate Y;Ueda Y
• 通讯作者: Ueda Y